Citius Oncology, Inc. (CTOR): R&D Expense
$6.42M
Year ended 2025-09-30
$3.39M
Trailing 12 months to 2026-06-30
| Period ended | R&D Expense | Change YoY | Source filing |
|---|---|---|---|
| 2025-09-30 | $6.42M | +30.3% | 2025-12-23, From 2024-10-01 |
| 2024-09-30 | $4.93M | +16.1% | 2025-12-23, From 2023-10-01 |
| 2023-09-30 | $4.24M | n/a | 2024-12-27, From 2022-10-01 |
R&D Expense at similar companies
| Company | Year ended | R&D Expense | Change YoY |
|---|---|---|---|
| Citius Oncology, Inc. (CTOR) | 2025-09-30 | $6.42M | +30.3% |
| iBio, Inc. (IBIO) | 2026-06-30 | $19.64M | +136.3% |
| Minerva Neurosciences, Inc. (NERV) | 2025-12-31 | $5.76M | -51.6% |
| Tenax Therapeutics, Inc. (TENX) | 2025-12-31 | $32.67M | +157.1% |
| Immix Biopharma, Inc. (IMMX) | 2025-12-31 | $16.26M | +44.0% |
| Aytu Biopharma, Inc (AYTU) | 2026-06-30 | $0 | -100.0% |
| Celularity Inc (CELU) | 2025-12-31 | $15.03M | -13.6% |
| Arbutus Biopharma Corp (ABUS) | 2025-12-31 | $25.24M | -53.3% |
| Journey Medical Corp (DERM) | 2025-12-31 | $480.0K | -95.1% |
Compare CTOR, IBIO, NERV, TENX side by side · Screen every company in Pharmaceutical Preparations ↗